Moderna completed enrollment of phase 3 COVE study of mRNA vaccine against COVID-19
On Oct. 22, 2020, Moderna announced that it had completed enrollment of 30,000 participants for the Phase 3…
-
-
BARDA reselected ICON as preferred partner to help strengthen U.S. emergency preparedness and response
On Oct. 19, 2020, ICON announced that it had been re-selected by the Biomedical Advanced Research and Development…
-
NIH RADx initiative advanced six new COVID-19 testing technologies
On Oct. 6, 2020, the National Institutes of Health (NIH), working in collaboration with the Biomedical Advanced Research…
-
Moderna announced supply agreement with U.S. Government for initial 100 million doses of mRNA vaccine against COVID-19
On Aug. 11, 2020, Moderna announced that the U.S. government had secured 100 million doses of mRNA-1273. The…
-
BARDA procured Regeneron’s REGN-EB3 investigational Ebola treatment for national preparedness
On Jul. 29, 2020, Regeneron announced that the Biomedical Advanced Research and Development Authority (BARDA) had entered into…
-
Emergent BioSolutions signed agreement with AstraZeneca to expand manufacturing for COVID-19 Vaccine candidate
On Jul. 27, 2020, Emergent BioSolutions announced that it had signed an agreement to provide contract development and…
-
Moderna announced expansion of BARDA agreement to support larger phase 3 program for vaccine (mRNA-1273) against COVID-19
On Jul. 26, 2020, Moderna announced a modification to its contract with the Biomedical Advanced Research and Development…
-
BD partnered with U.S. Government on $70 million manufacturing infrastructure project for mass vaccination campaigns
On Jul. 8, 2020, BD (Becton, Dickinson) announced the formation of a strategic, public-private partnership with the Biomedical…
-
Regeneron announced manufacturing and supply agreement for BARDA and U.S. DoD for REGN-COV2 anti-viral antibody cocktail
On Jul. 7, 2020, Regeneron announced that, as part of Operation Warp Speed, the Biomedical Advanced Research and…
-
Altimmune announces dosing of first patient in phase 1b clinical trial of NasoShield single dose intranasal anthrax vaccine candidate
On Jun. 30, 2020, Altimmune announced dosing of the first patient in the Company’s Phase 1b clinical trial…
-
SIGA Technologies announced deliveries of oral TPOXX to HHS valued at approximately $32 million
On Jun. 25, 2020, SIGA Technologies announced the deliveries of oral TPOXX (tecovirimat) to the U.S. Department of…
-
Quidel received BARDA funding to develop point-of-care diagnostic assay that includes COVID-19
On Jun. 11, 2020, Quidel announced it had received funding from the Biomedical Advanced Research and Development Authority…
-
OraSure received BARDA funding for Coronavirus Antibody ELISA using oral fluid samples
On Jun. 10, 2020, OraSure Technologies announced it had been awarded a $629,217 contract from the Biomedical Advanced…
-
Emergent BioSolutions joined U.S. Government’s Warp Speed Program for COVID-19 vaccine development and manufacturing
On Jun. 1, 2020, Emergent BioSolutions announced it had been issued a task order under an existing contract…
-
Moderna announced first participants in each age cohort dosed in phase 2 study of mRNA vaccine against novel Coronavirus
On May 29, 2020, Moderna announced the first participants in each age cohort had been dosed in the…
-
Phlow Corp was awarded $354 million BARDA contract to manufacture essential medicines in shortage
On May 19, 2020, Phlow, a U.S.-based, public benefit drug manufacturing corporation, received federal government funding of $354…
-
Mayo Clinic received $26 million from BARDA for COVID-19 convalescent plasma expanded access program
On May 4, 2020, Mayo Clinic was awarded a $26 million contract from the Biomedical Advanced Research and…
-
InBios obtained BARDA funding to develop point-of-care COVID-19 test
On Apr. 30, 2020, InBios announced that it had been awarded a contract from the Biomedical Advanced Research…
-
Moderna announced IND Submitted to FDA for phase 2 study of mRNA vaccine (mRNA-1273) against novel Coronavirus
On Apr. 27, 2020, Moderna announced it had submitted an Investigational New Drug application to the U.S. Food…
-
BARDA, Tangen Biosciences partnership pursues SARS-CoV-2 diagnostic
On Apr. 22, 2020, the Biomedical Advanced Research and Development Authority (BARDA) and Tangen Biosciences announced teaming up…
-
Moderna announced BARDA award for up to $483 million to accelerate development of mRNA vaccine (mRNA-1273) against novel Coronavirus
On Apr. 16, 2020, the U.S. government announced it will fund development of an experimental coronavirus vaccine from…
-
FDA accepted for Priority Review Biologics License Application for REGN-EB3 to treat Ebola
On Apr. 16, 2020, Regeneron announced the U.S. Food and Drug Administration (FDA) had accepted for Priority Review…
-
Nanomix awarded BARDA contract for development of rapid, mobile, point-of-care assays to detect COVID-19
On Apr. 8, 2020, Nanomix announced that the company had been awarded $570,000 in funding from Biomedical Advanced…
-
OraSure Technologies received BARDA contract for Rapid Oral Fluid Pan-SARS-Coronavirus in-home self-test
On Apr. 6, 2020, OraSure Technologies announced it had been awarded a $710,310 contract from the Biomedical Advanced…
-
Emergent BioSolutions partnered with U.S. Government to expedite development of plasma-derived therapy for COVID-19
On Apr. 2, 2020, Emergent BioSolutions announced it had entered into a formal partnership with the U.S. government…
-
Philips to fulfill contract with the HHS for the delivery of 10,000 Trilogy Universal units with accelerated delivery
On Mar. 31, 2020, Philips announced that it was fully committed to fulfill the contract with the U.S….
-
Cue Health awarded $13 million for rapid, portable, point-of-Care COVID-19 test by BARDA
On Mar. 31, 2020, Cue Health announced that is had been awarded up to $30 million in base…
-
Altimmune and the University of Alabama at Birmingham to collaborate on development of single-dose, intranasal COVID-19 vaccine
On Mar. 30, 2020, Altimmune announced that it was launching a collaboration with the University of Alabama at…
-
Roche initiated phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia
On Mar. 19, 2020, Roche announced it was working with the U.S. Food & Drug Administration (FDA) to…
-
Mesa Biotech received funding from HHS for development of a 30 minute molecular point-of-care SARS-CoV-2 test
On Mar. 19, 2020, Mesa Biotech announced it has significantly expanded its capacity to test clinical samples for…
